Elena Zamagni

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)

Gastone Castellani, Daniel Remondini, Giovanni Martinelli, 2015, Oncotarget.

Learned Deep Radiomics for Survival Analysis with Attention

Stephane Chauvie, Thomas Carlier, Diana Mateus, 2020, PRIME@MICCAI.

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.

Bart Barlogie, Monika Engelhardt, Niels Abildgaard, 2017, The Lancet. Oncology.

First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.

Sante Tura, Michele Cavo, Patrizia Tosi, 2004, Haematologica.

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

Jian Hou, Bart Barlogie, Michele Cavo, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Hans Erik Johnsen, Giampaolo Merlini, Robert A Kyle, 2014, The Lancet. Oncology.

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

Vincenzo Callea, Mario Boccadoro, Sara Bringhen, 2006, The Lancet.